ArticleTranslational lung cancer research2026
Prognostic value of ROS1 rearrangement in lung adenocarcinoma stratified by clinicopathologic and radiological features: a retrospective cohort study.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic significance of ROS1 rearrangement in lung adenocarcinoma (LUAD) remains a subject of debate. This study systematically evaluated the clinicopathologic characteristics and prognostic impact of ROS1 rearrangement in early- and advanced-stage LUAD, stratified by distinct clinicopathologic and radiological features. Methods: We retrospectively analyzed comprehensive clinical data and follow-up records of patients with resected invasive LUAD who underwent ROS1 testing between 2018 and 2020. Patients were stratified by tumor stage (I Results: Among 3,162 enrolled patients, 145 (4.5%) were ROS1 rearrangement-positive. ROS1 rearrangement was associated with non-smoking status, pure solid nodules, poor differentiation, and lymphovascular invasion. ROS1 rearrangement was associated with significantly worse recurrence-free survival (RFS) and overall survival (OS) in patients with stage II-III disease, solid radiographic pattern, poor differentiation, and aggressive pathologic features. In contrast, RFS and OS were comparable between ROS1-positive and -negative patients in the stage I, part-solid, moderately differentiated, and passive pathologic subgroups. Multivariable Cox regression further confirmed these subgroup-specific findings. The rate of bone metastasis was significantly higher in ROS1 rearrangement-positive than in ROS1 rearrangement-negative patients. Conclusions: ROS1 rearrangement plays a significant prognostic role in advanced progression of LUAD; however, the generally favorable survival outcomes of early-stage LUAD may obscure its prognostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.